Alliance Global Partners downgraded Alimera Sciences (ALIM) to Neutral from Buy after the company agreed to be bought by ANI Pharmaceuticals (ANIP) for $381M, or $5.50 per share, in cash upfront plus a CVR.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- ANI Pharmaceuticals sees ‘substantial accretion’ from Alimera Sciences deal
- ANI Pharmaceuticals to acquire Alimera Sciences for $381M upfront
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)